恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化*

doi:10.3969/j.issn.1672-5069.2022.05.009

摘要/Abstract

摘要： 目的探讨血清 HBV 共价闭合环状 DNA(HBV cccDNA)和HBV前基因组 RNA(HBV pgRNA)水平预测血清HBeAg阳性慢性乙型肝炎(CHB)患者接受恩替卡韦治疗后疗效的临床价值。方法 2018年1月～2020年1月我院收治的HBeAg阳性CHB患者89例,均口服恩替卡韦分散片治疗48 w。使用COOBAS TAQMAN和COBAS Amliprep系统和采用荧光定量PCR法检测血清HBV cccDNA和HBV pgRNA水平,采用化学发光法定量检测血清HBsAg和HBeAg水平。应用受试者工作特征曲线(ROC)分析血清各指标预测恩替卡韦治疗的CHB患者疗效的价值。结果 89例HBeAg阳性CHB患者经恩替卡韦治疗48 w后,获得病毒学应答85例(95.5%),生化学应答80例(89.9%),血清学应答9例(10.1%);获得完全应答75例(84.3%);完全应答组血清ALT、HBsAg、HBeAg、HBV DNA, HBV cccDNA和HBV pgRNA水平分别为(228.3±34.9)U/L、(2.5±0.4)lg IU/mL、(18.6±1.9)S/CO、(6.1±0.6)lg IU/mL、(2.2±0.2)cps/mL和(4.5±0.6)cps/mL,与非完全应答组【分别为(69.5±17.1)U/L、(3.7±0.7)lg IU/mL、(163.2±16.3)S/CO、(6.8±0.7)lg IU/mL、(3.9±0.4)cps/mL和(7.0±0.7)cps/mL】比,差异显著(P＜0.05);应用血清HBV cccDNA与HBV pgRNA水平联合预测CHB患者接受恩替卡韦治疗疗效的ROC曲线下面积为0.892,其敏感性为81.6%,特异性为89.5%。结论在抗病毒治疗前,检测HBeAg阳性慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平预测疗效有一定的应用价值,值得进一步研究。

关键词: 慢性乙型肝炎, 恩替卡韦, HBeAg, HBV 共价闭合环状 DNA, HBV前基因组 RNA, 治疗

Abstract: Objective The aim of this study was to investigate the clinical implication of serum HBV covalently closed circular DNA (HBV cccDNA) and HBV pregenomic RNA (HBV pgRNA) in patients with chronic hepatitis B (HBV) undergoing entecavir therapy. Methods A total of 89 patients with serum HBeAg-positive CHB were admitted to our hospital between January 2018 and January 2020, and all received entecavir therapy for 48 weeks. Serum HBV cccDNA, HBV pgRNA and HBV DNA loads were detected by fluorescent quantitative PCR under COOBAS TAQMAN and COBAS Amliprep systems. Serum HBsAg and HBeAg levels were detected by chemiluminescence method. The predicting performance of each parameter was analyzed by receiver operating characteristic (ROC) curve. Results At the end of 48 week observation, the virologic response was obtained in 85 cases(95.5%), biochemical response was obtained in 80 cases (89.9%), and serologic response in 9 cases (10.1%); the complete response (CR) as defined by both virologic and biochemical responses was gained in 75 cases(84.3%); at presentation, serum ALT, HBsAg, HBeAg, HBV DNA, HBV cccDNA and HBV pgRNA levels in patients with CR were (228.3±34.9)U/L, (2.5±0.4)lg IU/mL, (18.6±1.9)S/CO, (6.1±0.6)lg IU/mL, (2.2±0.2)cps/mL and (4.5±0.6)cps/mL, significantly different compared to [(69.5±17.1)U/L, (3.7±0.7)lg IU/mL, (163.2±16.3)S/CO,(6.8±0.7)lg IU/mL, (3.9±0.4)cps/mL and (7.0±0.7)cps/mL, respectively, P<0.05]; the area under ROC of serum HBV cccDNA and HBV pgRNA combination in predicting CR in patients with CHB receiving entecavir treatment was 0.892, with the sensitivity of 81.6% and specificity of 89.5%. Conclusion The combined detection of serum HBV cccDNA and HBV pgRNA is of high predictive value in patients with HBeAg-positive CHB before antiviral therapy, which needs further clinical investigation.

Key words: Hepatitis B, Entecavir, HBeAg positive, HBV cccDNA, HBV pgRNA, Therapy

王春莹, 屈耀宁, 乔炜, 刘静静, 胡颖辉. 恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 641-644.

Wang Chunying, Qu Yaoning, Qiao Wei, et al.. Implication of serum HBV cccDNA and HBV pgRNA in patients with chronic hepatitis B receiving entecavir therapy[J]. Journal of Practical Hepatology, 2022, 25(5): 641-644.

参考文献

[1]Pietro L,Massimo C. Nucleos(t)ide analog therapy of chronic hepatitis B and liver cancer riskreduction: better nucleotides than nucleosides. Gastroenterology,2019,157(6):1682-1684.
[2]田贤江,赵立夫,沈跃飞,等. 恩替卡韦治疗HBV DNA低水平HBeAg阳性慢性乙型肝炎可抑制病毒复制及改善肝组织学病变. 中华临床感染病杂志,2019,12(2):107-110.
[3]Liem K S,Van Campenhout M J H,Xie Q,et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther,2019,49(4):448-456.
[4]刘如玉,李明慧,谢尧,等. HBeAg阴性初治慢乙型肝炎患者恩替卡韦4年抗病毒治疗FIB-4评分动态变化研究. 中华实验和临床病毒学杂志,2020,34(1):51-56.
[5]Zhang D,Wang Y,Zhang H Y,et al. Histone deacetylases and acetylated histone H3 are involved in the process of hepatitis B virus DNA replication. Life Sci,2019,223(15):1-8.
[6]Liu Y,Feng J,Sun M,et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett,2019,454(29):16-19.
[7]Chen E Q,Wang M L,Tao Y C,et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat,2019,26(5):586-595.
[8]Yanpin M,Xuli B,Fang X,et al. The effect of thymopentin add-on in hepatitis B e antigen positive chronic hepatitis B after virus suppression by peginterferon plus entecavir therapy. Cell Mol Biol,2019,65(2):75-81.
[9]中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[10] 谢知兵,周建亮,于红缨,等. HBV前基因组RNA检测在乙型肝炎治疗中的临床研究. 中华医院感染学杂志,2020,19(5):26-29.
[11] 王颖,赵奎,秦建忠. HBV cccDNA,HBsAg,HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值. 临床肝胆病杂志,2020, 36(5):57-62.
[12] 蒋贝,刘畅,苏瑞,等. 血清HBV RNA在HBeAg阴性慢性乙型肝炎患者中的检测价值. 中华肝脏病杂志,2019,27(9):668-672.
[13] Nkongolo S, Nubaum L,Lempp FA,et al. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Res,2019,168(12):146-155.
[14] 饶希,施欢欢,吴振平,等. 长期核苷酸类似物治疗的慢性乙型肝炎患者血清HBV pgRNA与抗原状态变化的相关性研究.中华肝脏病杂志,2021,29(8):766-770.
[15] Lin N,Ye A,Lin J,et al. Diagnostic value of serum pgRNA detection in HBV-infected patients with different clinical outcomes. J Clin Microbiol,2019,58(2):24-26.
[16] 鲁凤民,王杰,陈香梅,等. 新型血清指标在乙型肝炎创新药物研发中的应用. 中华肝脏病杂志,2020,28(8):649-653.
[17] 缪晓辉,裴彬,周璐靖. 核苷类药物抗HBV治疗安全停药的预测指标. 中华传染病杂志,2019,37(12):707-710.
[18] 扆琳珠,史晓红,王丹丹,等. HBsAg阳性母亲PBMC HBV cccDNA对新生儿Th1/Th2型细胞因子的影响. 中华疾病控制杂志,2019,23(6):700-705.
[19] Liu Y,Feng J,Sun M,et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett,2019,454(29):158-170.
[20] 谢知兵,周建亮,于红缨,等. HBV前基因组RNA检测在乙型肝炎治疗中的临床研究. 中华医院感染学杂志,2020,30(5):693-697.
[21] Carey I, Gersch J,Wang B,et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology,2020,72(1):42-57.

恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化^*

Implication of serum HBV cccDNA and HBV pgRNA in patients with chronic hepatitis B receiving entecavir therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	南月敏, 李佳峥. 肝硬化与感染[J]. 实用肝脏病杂志, 2022, 25(5): 609-611.
[2]	罗楠, 李荣宽. 肝硬化并发自发性细菌性腹膜炎诊治现状[J]. 实用肝脏病杂志, 2022, 25(5): 616-619.
[3]	王玉珊, 孔银, 刘元元, 刘天府, 麻爱娣, 张亚萍, 李永芳, 张岭漪. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响:单中心回顾性研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 633-636.
[4]	徐欢, 谭钧元, 黄荷, 董丹丹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及其外周血单个核细胞TLR4和B7-H1表达变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 637-640.
[5]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[6]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[7]	李季, 周仲松, 郜玉峰, 薛继华, 张骏飞. 超声融合导航技术指导微波消融治疗小肝癌临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 698-701.
[8]	张凯, 刘培培, 饶石磊, 王琦, 岳恺, 王旸, 杨峥, 张松. 三维适形放射治疗不同大体肿瘤体积的原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 710-713.
[9]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[10]	周宇, 耿进朝, 韩雪, 于建华, 回瑾, 李岩, 李微. 射频消融治疗原发性肝癌患者疗效评价^*[J]. 实用肝脏病杂志, 2022, 25(5): 718-721.
[11]	任文妍, 赵森, 庄琰, 杜森, 李秋实. 血液抽吸联合射频消融治疗肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 726-729.
[12]	方骏, 王安, 孙修勇, 孙春辉, 张炳远, 朱武晖. 三镜联合分期手术与腹腔镜手术治疗老年胆总管结石合并胆囊结石患者疗效对比研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 730-733.
[13]	迪力旦·纳斯尔, 赵亮, 尼加提江·艾比不拉, 排祖拉·沙拉依阿当. 胆肠Roux-en-Y吻合术留置皮下空肠盲袢治疗肝内胆管结石患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 734-737.
[14]	郭景龙, 石保昌, 张洪战. 胆肠Roux-en-Y吻合术联合留置皮下空肠盲袢取石治疗肝内胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 738-741.
[15]	杜加录, 张凯, 路志宇, 高建华. 完全腹腔镜胆总管囊肿切除术和不同胆道重建术临床效果研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 742-745.